At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BLTE Belite Bio, Inc.
Trading 10-15 15:42:29 EDT
155.00
+2.28
+1.49%
High155.47Low152.20Vol153.11K
Open153.87D1 Closing152.72Amplitude2.14%
Mkt Cap6.24BTradable Cap3.03BTotal Shares40.27M
T/O23.66MT/O Rate0.78%Tradable Shares19.55M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals (VRTX) and Corcept Therapeutics (CORT)
TIPRANKS  ·  10-15 19:40
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals (VRTX) and Corcept Therapeutics (CORT)
Belite Bio Seeks Tinlarebant Approval in Singapore, UK and Switzerland
Reuters  ·  10-15 04:01
Belite Bio Seeks Tinlarebant Approval in Singapore, UK and Switzerland
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
THOMSON REUTERS  ·  10-15 04:00
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio - U.S. Nda for Tinlarebant Accepted with Pdufa Target Action Date February 12, 2027
THOMSON REUTERS  ·  10-15 04:00
Belite Bio - U.S. Nda for Tinlarebant Accepted with Pdufa Target Action Date February 12, 2027
Belite Bio - Submits Marketing Authorization Applications for Tinlarebant in Singapore, UK, and Switzerland
THOMSON REUTERS  ·  10-15 04:00
Belite Bio - Submits Marketing Authorization Applications for Tinlarebant in Singapore, UK, and Switzerland
Belite Bio Chief Medical Officer Hendrik Peter Scholl Reports ADS Disposal Valued at $80,048.70
Reuters  ·  10-06
Belite Bio Chief Medical Officer Hendrik Peter Scholl Reports ADS Disposal Valued at $80,048.70
Belite Bio (BLTE) Draws Fresh Valuation Attention After FDA Priority Review And Euretina Spotlight
Simply Wall St.  ·  10-01
Belite Bio (BLTE) Draws Fresh Valuation Attention After FDA Priority Review And Euretina Spotlight
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
GlobeNewswire  ·  10-01
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio to Present Phase 3 Dragon Topline Results for Tinlarebant in Adolescent Stargardt Disease at Euretina
Reuters  ·  09-29
Belite Bio to Present Phase 3 Dragon Topline Results for Tinlarebant in Adolescent Stargardt Disease at Euretina
Belite Bio CFO Chuang Hao-Yuan Sells USD 8.85 Million in Common Shares
Reuters  ·  09-10
Belite Bio CFO Chuang Hao-Yuan Sells USD 8.85 Million in Common Shares
Mizuho Raises Price Target on Belite Bio to $234 From $220, Keeps Outperform Rating
MT Newswires Live  ·  09-09
Mizuho Raises Price Target on Belite Bio to $234 From $220, Keeps Outperform Rating
U.S. Research Roundup-Argan, Mastec, Oracle
Reuters  ·  09-09
U.S. Research Roundup-Argan, Mastec, Oracle
Belite Bio Price Target Raised to $245.00/Share from $214.00 by HC Wainwright & Co.
Dow Jones  ·  09-08
Belite Bio Price Target Raised to $245.00/Share from $214.00 by HC Wainwright & Co.
Belite Bio, Inc : H.c. Wainwright Raises Target Price to $245 from $214
THOMSON REUTERS  ·  09-08
Belite Bio, Inc : H.c. Wainwright Raises Target Price to $245 from $214
Belite Bio submits NDA to MHLW in Japan for tinlarebant in STGD1
TIPRANKS  ·  09-08
Belite Bio submits NDA to MHLW in Japan for tinlarebant in STGD1
Belite Bio Files Japan NDA for Tinlarebant Under Sakigake Designation for Stargardt Disease Type 1
Reuters  ·  09-08
Belite Bio Files Japan NDA for Tinlarebant Under Sakigake Designation for Stargardt Disease Type 1
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan Under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
THOMSON REUTERS  ·  09-08
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan Under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio, - FDA Accepts Nda with Priority Review for Tinlarebant; Pdufa Target Date Feb 12, 2027
THOMSON REUTERS  ·  09-08
Belite Bio, - FDA Accepts Nda with Priority Review for Tinlarebant; Pdufa Target Date Feb 12, 2027
Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)
TIPRANKS  ·  09-06
Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)
Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating
MT Newswires Live  ·  09-05
Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating

Introduction

Company Name.
Belite Bio, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Issue price:
--